NPM1 and acute myeloid leukemia: The addition of GO to intensive chemotherapy in NPM1-mutated AML has been shown to lead to better clearance of the NPM1 transcript level, resulting in a lower relapse rate (4-yr CIR 29.3% vs. 45.7%, p = 0.009) [64].